1-3 of 3
Alan K. Burnett
Close
Sort by
Journal Articles

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

Mike Dennis, Ian F. Thomas, Cono Ariti, Laura Upton, Alan K. Burnett, Amanda Gilkes, Rohini Radia, Claire Hemmaway, Priyanka Mehta, Steven Knapper, Richard E. Clark, Mhairi Copland, Nigel Russell, Robert K. Hills
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5621–5625.
https://doi.org/10.1182/bloodadvances.2021005038
Published: 2021
Includes: Supplemental data
Journal Articles

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3052–3061.
https://doi.org/10.1182/bloodadvances.2019000197
Published: 2019
Includes: Supplemental data
Journal Articles

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Claire M. Lucas, Laura J. Scott, Natasha Carmell, Alison K. Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark
Journal: Blood Advances
Blood Adv (2018) 2 (9): 964–968.
https://doi.org/10.1182/bloodadvances.2017013615
Published: 2018
Includes: Supplemental data